Saturday 17 October 2026
Export VRAX’s income statement to Excel — free account
Virax Biolabs Group Limited
VRAX Healthcare Biotechnology
Virax Biolabs Group Limited’s revenue for fiscal 2026 (year ended March 2026) was $12,400.00, up 96.8% from fiscal 2025.
1.45
0.17
−10.49%
Follow VRAX
| Mar '26 | Sep '25 | Mar '25 | Sep '24 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 0.00% | 0.00% | 0.00% |
+7 more TTM periods Free account |
|
| 0.00% | 0.00% | 0.00% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(15.11) | (17.44) | (18.48) | (17.50) | |
Capital Expenditures |
(1.25) | (1.95) | (2.30) | (1.69) | |
| Other line items | |||||
Cash ROIC |
(109.51%) | (202.40%) | (190.11%) | (109.86%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | 0.00% | — | — | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
0.61 | 0.64 | 0.40 | 0.23 | |
Capex/Depreciation |
(1.08) | (2.37) | (3.69) | (6.07) | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates